• Quotes
  • Shortcuts
The Executive's Internet
Fri, Sept 25th
editor corner icon Editor's Corner | Archive
The time is now: Automating the back office through the cloud: COVID-19 has changed the game. Leaders will need to reshape their companies for the new normal, making the promise of agility and market responsiveness an actual reality. Patricia
icon
GoogleAmazonWikipedia
site of the day icon Site of the Day | Archive
Time Traveler
See which words were first recorded by year. Or search for other words by the year when they were first used.


spacerspacer

 

 BUSINESS/FINANCE NEWS
Setup News Ticker
   BUSINESS/FINANCE NEWS
Searching for 'Market trade'. (Return)

MarketWatch MarketPulseSep 25, 2020
Stocks open mostly lower on rising case counts, stimulus stalemate
U.S. stocks opened mostly lower Friday morning as investors hunted for a positive catalyst amid an array of headwinds. The Dow Jones Industrial Average lost about 135 points or 0.5% to open near 26,680, while the S&P 500 slipped 10 points, 0.3%, opening near 3,237. The Nasdaq Composite was about 10 points higher, near 10,680, a gain of 0.1%. Stock benchmarks are on track to mark a fourth straight week of losses as concerns grow over the U.S. election, the lack of additional stimulus to support the economy, and rising COVID-19 case counts around the globe. Orders for durable goods rose 0.4% in August, the Commerce Department said Friday, signaling slowing momentum in the economy. Shares of NVIDIA Corporation rose in early trade after a price-target increase. The chipmaker is the S&P 500 component that's gained the most in the year to date - 110%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



MarketWatch MarketPulseSep 25, 2020
Amesite's stock opens below IPO price, than rallies above it
Amesite Inc.'s stock stumbled out of the gate, as it opened 1% below its initial public offering price, but then righted itself to trade higher. The first trade was at $4.95 at 11:39 a.m. Eastern for 162,143 shares, below the IPO price of $5. The stock was last trading 10% above its IPO price. The company's IPO priced at the midpoint of the expected range of $4.50 to $5.50. The company sold 3 million shares to raise $15 million. With 20.4 million shares outstanding after the IPO, the artificial-intelligence driven platform and course designer was valued at $102.1 million. Laidlaw & Co. was the sole book-running manager. The company went public at a time that the Renaissance IPO ETF has rallied 23.5% over the past three months, while the S&P 500 has gained 5.6%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



Yahoo BusinessSep 25, 2020
Novavax initiates late-stage COVID-19 vaccine trial in UK
For those that thought the extreme market volatility was behind us, think again. This month, another burst of volatility was brought on by concerns about the U.S. economic recovery, hefty valuations, and a second wave of COVID-19. While challenging at times, Wall Street pros believe the healthcare space is becoming more exciting, with several long-term tailwinds on the horizon.As healthcare stocks tend to be riskier in nature, we narrowed our search to include only the best of the best, according to the analyst community.TipRanks' database revealed three such stocks that won't break the bank; each one trades for less than $5 per share and has earned a "Strong Buy" consensus rating from the Street's pros. Not to mention triple-digit upside potential is on the table here.VYNE Therapeutics (VYNE)Using its Molecule Stabilizing Technology (MST) platform, VYNE Therapeutics hopes to solve some of the most difficult therapeutic challenges. Given the strong performance of one of its products and its $1.52 share price, some members of the Street think that now is the time to snap up shares.Singing the healthcare name's praises is Cantor analyst Louise Chen. "We continue to believe the market opportunity for VYNE's products and pipeline are underappreciated. Therefore, upwards earnings revisions and multiple expansion should drive VYNE shares higher, in our view," the analyst opined.Chen is particularly excited about Amzeeq, which is the first topical minocycline product in the U.S. designed
TRENDING TAGS
StocksBuy Market Dow futures European
Stockmarket Buy Today futures Higher
Coronaviruslatest vaccine cases pandemic Fox
PandemicDuring coronavirus live How Stocks
ChinaElectric FTSE index Bytedance bottled
Appletax Watch Commission EU Billion
COVID-19vaccine should tests UK pandemic
marketStock Stocks Dow futures Snapshot
FacebookElection Will Twitter Groups LinkedIn
TodayStock USA Stocks shooting best

NEWS SOURCES
Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money
CNN/Money Real Estate News
Dismal.com: Analysis
Dismal.com: Indicators
Enterprise Application News
Entrepreneur.com
Forbes Headlines
Forbes Social Media News
FT.com - China, Economy & Trade
FT.com - Financial Markets
FT.com - Hedge Funds
FT.com - Telecoms
FT.com - US
Google Business News
Google Market News
HBS Working Knowledge
Inc.com
INSEAD Knowledge
International Tax Review
Kiplinger
Knowledge@Wharton
L.S. Starrett News
MarketWatch
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly
MSNBC.com: Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
OpinionJournal.com
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money
SEC.gov Updates: News Digest
SHRM HR News
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ US News
WSJ World Markets
Yahoo Business
  • CEOExpress
  • 1 Boston Place | Suite 2600
    Boston MA 02108
  • 617 482 1200
    617 299 8649 (fax)
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.

©1999-2020 CEOExpress Company LLC